vs
华钦科技（CLPS）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
华钦科技的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$82.8M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 0.2%，领先383.8%）
华钦科技（CLPS Inc）是全球领先的信息技术咨询与数字化解决方案服务商，核心服务银行、保险、资产管理等金融领域客户，同时覆盖零售、医疗健康、电商等行业，业务遍及北美、亚太及欧洲地区。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CLPS vs RIGL — 直观对比
营收规模更大
CLPS
是对方的1.2倍
$69.8M
净利率更高
RIGL
高出383.8%
0.2%
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $82.8M | $69.8M |
| 净利润 | $183.0K | $268.1M |
| 毛利率 | 23.1% | 91.5% |
| 营业利润率 | 0.2% | 33.2% |
| 净利率 | 0.2% | 384.0% |
| 营收同比 | — | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | — | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLPSRIGL
| Q2 26 | $82.8M | — | ||
| Q4 25 | — | $69.8M | ||
| Q3 25 | — | $69.5M | ||
| Q2 25 | — | $101.7M | ||
| Q1 25 | — | $53.3M | ||
| Q4 24 | $71.8M | $57.6M | ||
| Q3 24 | — | $55.3M | ||
| Q2 24 | — | $36.8M |
净利润CLPSRIGL
| Q2 26 | $183.0K | — | ||
| Q4 25 | — | $268.1M | ||
| Q3 25 | — | $27.9M | ||
| Q2 25 | — | $59.6M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | $-993.5K | $14.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | $-1.0M |
毛利率CLPSRIGL
| Q2 26 | 23.1% | — | ||
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | 21.9% | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% |
营业利润率CLPSRIGL
| Q2 26 | 0.2% | — | ||
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | -1.3% | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% |
净利率CLPSRIGL
| Q2 26 | 0.2% | — | ||
| Q4 25 | — | 384.0% | ||
| Q3 25 | — | 40.2% | ||
| Q2 25 | — | 58.6% | ||
| Q1 25 | — | 21.5% | ||
| Q4 24 | -1.4% | 24.9% | ||
| Q3 24 | — | 22.5% | ||
| Q2 24 | — | -2.8% |
每股收益（稀释后）CLPSRIGL
| Q2 26 | — | — | ||
| Q4 25 | — | $14.11 | ||
| Q3 25 | — | $1.46 | ||
| Q2 25 | — | $3.28 | ||
| Q1 25 | — | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | — | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.1M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $57.6M | $391.5M |
| 总资产 | $118.1M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CLPSRIGL
| Q2 26 | $29.1M | — | ||
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | $31.2M | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M |
总债务CLPSRIGL
| Q2 26 | — | — | ||
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M |
股东权益CLPSRIGL
| Q2 26 | $57.6M | — | ||
| Q4 25 | — | $391.5M | ||
| Q3 25 | — | $117.6M | ||
| Q2 25 | — | $81.9M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | $63.9M | $3.3M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-29.9M |
总资产CLPSRIGL
| Q2 26 | $118.1M | — | ||
| Q4 25 | — | $513.6M | ||
| Q3 25 | — | $242.5M | ||
| Q2 25 | — | $206.7M | ||
| Q1 25 | — | $176.0M | ||
| Q4 24 | $110.0M | $164.0M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | — | $128.4M |
负债/权益比CLPSRIGL
| Q2 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLPSRIGL
| Q2 26 | — | — | ||
| Q4 25 | — | $22.0M | ||
| Q3 25 | — | $24.0M | ||
| Q2 25 | — | $30.5M | ||
| Q1 25 | — | $-893.0K | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | — | $302.0K |
现金转化率CLPSRIGL
| Q2 26 | — | — | ||
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
